HP5 TREATMENT PATTERNS AMONG POSTMENOPAUSAL OSTEOPOROTIC WOMEN STARTING ON DAILY OR WEEKLY BISPHOSPHONATE THERAPY  by Huybrechts, KF et al.
A11Abstracts
brovascular accidents and death. The expected costs were cal-
culated for 2005 from the perspective of the UK NHS. Each
event was associated with a transient decrement in health-related
utility due to recurrent symptoms while waiting for a repeat
intervention and to pain and distress of events or further inter-
ventions, relative to a baseline asymptomatic coronary heart
disease value based on the ARTS and SoS trials. A probabilistic
sensitivity analysis was undertaken. RESULTS: Although the
price premium of Endeavor is above £500, the total cost of
Endeavor treatment was only slightly higher at ﬁve years than
Driver (£6094 vs. £6058) due mainly to the reduced need for
revascularisations in the ﬁrst year. Endeavor was also associated
with QALY gains (0.0053 per patient), and therefore had an
incremental cost-effectiveness ratio of ~£6700/QALY. The prob-
ability of Endeavor being cost-effective at a threshold of
£30,000/QALY was 58%. CONCLUSIONS: This exploratory
analysis shows the Endeavor DES to be cost-effective. Results of
long-term trials are awaited to conﬁrm model predictions.
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OBJECTIVE: To determine the cost-effectiveness (CE) from the
Belgian societal perspective of anticoagulation with bivalirudin
vs. heparin + glycoprotein inhibitors (GPIIb/IIIa) in patients
undergoing percutaneous coronary intervention (PCI).
METHODS: Efﬁcacy data were taken from REPLACE-2, EPIS-
TENT and ESPRIT trials which documented probabilities of PCI
outcomes: death, myocardial infarction, urgent revasculariza-
tion, and major/minor bleedings according to TIMI deﬁnition.
Costs data were drawn from Belgian literature except for drug
costs which were valued using REPLACE-2 actual dosages and
ofﬁcial Belgian tariffs. We considered unfractionated (UFH) and
low-molecular weight (LMWH) heparins. Abciximab was the
only GPIIb/IIIa considered as it is the only one indicated for PCI
in Belgium. A 30-day time frame analytical model was developed
from an original model by The Swedish Institute for Health Eco-
nomics (IHE), to estimate the incremental costs per life year
gained (LYG). Costs and LYG were discounted at 3.0% per
annum. In the base case analysis, GPIIb/IIIa was given in 27.5%
of the patients receiving heparin (consensus estimate between the
Belgian Working Group in Interventional Cardiology and expert
opinions). RESULTS: Giving bivalirudin to the average patient
undergoing PCI in Belgium resulted in extra 0.0794LYG and
€90.1 vs. UFH (incremental cost-effectiveness ratio (iCER) =
€1134.8/LYG). LMWH was dominated. A threshold analysis,
varying from 0% to 100% the percentage of patients in the
heparin branches who receive additional GPIIb/IIIa, revealed
that when this percentage is above 34%, bivalirudin dominates
both heparin strategies. When no patient at all was given addi-
tional GPIIb/IIIa, the iCER vs. UFH was €3933.3/LYG. Other
variables were much less sensitive. CONCLUSION: Our analy-
sis suggests that the use of bivalirudin during PCI is a cost-effec-
tive alternative to the current approach of heparin + GP IIb/IIIa
in the Belgian health care setting. The percentage of patients
given GPIIb/IIIa with heparin is the key factor driving the iCER
of bivalirudin.
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OBJECTIVES: Primary bare metal stenting and abciximab infu-
sion are currently considered the best available reperfusion strat-
egy for acute ST-segment elevation myocardial infarction
(STEMI). Sirolimus eluting stents (SES), compared to bare metal
stent (BMS), greatly reduce the incidence of binary restenosis and
target vessel revascularisation (TVR), but their use on a routine
basis results in a signiﬁcant increase in medical costs. With
current European list prices, the use of tiroﬁban (TIRO) instead
of abciximab (AB) would save enough money to absorb the dif-
ference in cost between SES and BMS. The STRATEGY study
examined the safety and efﬁcacy of tiroﬁban and SES vs. AB and
BMS in STEMI patients. To evaluate the short- and medium-term
economic impact of the STRATEGY combination, namely TIRO
+ SES versus current golden standard of treatment, AB + BMS.
METHODS: A medium-term (one year or 8 months) decision
analytic model was developed to conduct a cost-effectiveness
analysis using a cost per survival. The perspective of the model
was that of Italy. Clinical outcomes (mortality, myocardial
infarction (MI), revascularization (Revasc) and major cardiac
events (MACE) were based on the ﬁnal results of the STRAT-
EGY study. Costs were obtained from Italian sources for device
and hospitalization data (€2004). Total expected costs and out-
comes for TIRO + SES versus AB + BMS were compared. The
robustness of the results was tested in a sensitivity analysis.
RESULTS: Clinical outcomes were lower for TIRO + SES when
compared to AB + BMS for mortality (0.079 vs. 0.089), MI
(0.068 vs. 0.089), Revasc (0.067 vs. 0.197) and MACE (0.214
vs. 0.377). The average overall cost of TIRO + DES (€23,674)
was less expensive than that of AB + BMS (€24,274) with an
incremental difference of €600. One-way sensitivity analysis
indicated the model was sensitive to the unit cost of AB with a
threshold value of €338. CONCLUSIONS: TIRO + SES resulted
to be the dominant strategy.
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OBJECTIVE: To compare treatment patterns, speciﬁcally per-
sistence and compliance, among postmenopausal osteoporotic
women treated with daily or weekly bisphosphonates.
METHODS: Data were obtained from a US managed care data-
base. The study cohort included women with an osteoporosis
diagnosis (ICD-9 code 733.0) followed by a prescription for
alendronate 10mg (daily) or 70mg (weekly), risedronate 5mg
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(daily) or 35mg (weekly) between January 2001 and June 2002.
The ﬁrst prescription for one of these medications was consid-
ered the index prescription. Non-persistence was deﬁned as a
>30 days gap between two subsequent prescriptions. Compliance
was measured using the medication possession ratio (MPR), with
analyses conducted using both continuous and categorical deﬁ-
nitions. Outcomes were compared between daily and weekly reg-
imens. RESULTS: Of the 2905 new users identiﬁed based on 
a 6-month run-in, 31% had an index prescription for a daily
regimen, 69% for a weekly regimen. After six months, 46.7%
of women on the weekly regimen and 41.9% on the daily
regimen persisted with their therapies. At 12 months, the per-
centages were 27.7% and 18.9%. Longer persistence was thus
observed for once-weekly users (median: 146 vs. 120 days), but
the differences were not signiﬁcant. At 12 months, weekly users
had a signiﬁcantly higher MPR than daily users (53.7% vs.
46.9%, P = 0.0022). Similarly, the proportion of highly compli-
ant patients (≥80%) was 23% for the daily versus 32% for the
weekly regimen (P = 0.0025). A larger proportion of patients
starting on a weekly regimen remained on the same treatment
over time (98% vs. 42% for those still treated at 12 months).
An average of 1.15 switches per patient was observed. CON-
CLUSIONS: Although higher rates of compliance are observed
for the weekly compared to the daily regimen, compliance and
persistence rates for both regimens are suboptimal, and the social
and economic implications of such behavior are known to be
substantial.
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OBJECTIVES: To examine effect of co-payment on compliance
among patients who initiated statins within 6-months of hospi-
tal discharge for coronary heart disease (CHD). METHODS:
Medstat Marketscan Commercial and Medicare 1999–2003
databases containing inpatient admission, outpatient and phar-
macy claims were utilized for this study. The ﬁrst ﬁll date of a
prescription for statins within 6 month following CHD hospi-
talization was identiﬁed as the index date. The study sample con-
sisted of adults who had no statin use during the year prior to
the CHD hospitalization and had at least 12 months of follow-
up after the index date. Medication possession ratio (MPR) was
calculated as the ratio of total days supply for statins to total
days during 12-month follow-up. Being compliant to statins was
deﬁned as having a MPR of 80% or greater. Effect of co-payment
on compliance to statins was examined by a multiple logistic
regression, controlling for age, gender, region, year of the index
date, type of CHD, concomitant co-morbidity and concomitant
use of other medications. RESULTS: In total, 5548 patients met
the inclusion criteria and were included in the analysis. In total,
3404 (61.36%) had a MPR of 80% or over and were consid-
ered compliant to statins. Compared with those who had a co-
payment of $10 or lower, patients with a co-payment over $20
were signiﬁcantly less likely to be compliant to statins (OR, 0.46;
95% CI, 0.40–0.54). Other factors signiﬁcantly associated with
compliance in the model were age, gender, region, hyperlipi-
demia, depression, concomitant use of non-statin lipid lowering
drugs and beta-blockers, and type of CHD. CONCLUSIONS:
High co-payment (>$20) appears to be a signiﬁcant barrier to
compliance to statins, even after adjusting for demographic and
clinical variables.
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OBJECTIVE: Poor patient outcomes associated with low levels
of adherence to medication have been previously reported in
several chronic conditions. In transplantation, inadequate
immunosuppression (IS) can lead to rejection and graft loss as
well as increased healthcare costs. We evaluated patient and
regimen characteristics associated with IS adherence in a private
payer transplant population. METHODS: U.S. commercial
claims data for de novo kidney, heart, liver, lung, pancreas and
kidney-pancreas recipients transplanted 1995–2003 were linked
to data from the Organ Procurement Transplant Network, a
national transplant registry. All patients had ≥1 IS reﬁll and were
followed up to 1-year post-transplant. Patients who switched
between study drugs were excluded. Medication adherence was
measured by the medication possession ratio (MPR) i.e. ratio of
number of therapy days supplied to number of follow-up days.
The Kaplan-Meier product-limit method was used to estimate
time to non-adherence. Adherence was deﬁned as having a MPR
≥ 90% and was modeled using multivariate logistic regression.
RESULTS: In total, 349 transplant recipients met study criteria.
Mean adherence to index IS therapy was 84% (MPR = 0.84).
Mean time to non-adherence was 8.4 months. Older age (OR =
1.03, p = 0.0005) and higher number of primary care visits (OR
= 1.02, p = 0.03) were associated with higher odds of adherence.
Hispanic ethnicity (OR = 0.34, p = 0.004), more co-morbidities
(OR = 0.90, p = 0.078), less than college education (OR = 0.66,
p = 0.07), or a greater number of other prescription medications
(OR = 0.95, p = 0.03) were associated with a lower likelihood
of adherence. Copay and gender were not signiﬁcantly associ-
ated with adherence. CONCLUSIONS: The mean level of adher-
ence to immunosuppressive therapy was in congruence with
previous ﬁndings for other chronic medications. Medication reﬁll
adherence was associated with age, race, co-morbidity index,
education status, primary care visits and number of medications
taken. Drug copay did not impact adherence to immunosup-
pression therapy in this transplant population.
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OBJECTIVES: Glycosylated hemoglobin (HbA1c) is a well-
established measure of glycemic control and evidence shows that
maintaining an acceptable HbA1c level may be associated with
lower rates of diabetic complications. Many countries have
established speciﬁc HBa1c target values indicative of good
glycemic control for patients with type-2 diabetes. This study
examined the characteristics of patients with type-2 diabetes and
investigated whether patients met the National Institute for Clin-
ical Excellence (NICE) recommended target. METHODS: Data
were obtained from the UK Mediplus Database. Patients identi-
ﬁed as having type-2 diabetes between January 1, 2004 and June
30, 2004 was included in the analysis. Co-morbidities and com-
plications were also examined. Use of antidiabetic medication
between April 1, 2004 and June 30, 2004 was reviewed. A subset
of the patients who received an HbA1c test was examined, as
